Redx Pharma hails new drug candidate for leukaemia and arthritis

Redx Pharma hails new drug candidate for leukaemia and arthritis

Seneca EIS portfolio company Redx Pharma has identified another potential blockbuster from its pipeline of drug candidates. Its oncology arm has found a would-be treatment for leukaemia and other blood cancers, and auto-immune diseases, such as lupus.

It is the second drug to come through the development system. Redx has 13 drug programmes in its pipeline.

Chief executive (CEO) Neil Murray said: “This drug candidate has the potential to demonstrate efficacy without the highly unpleasant side effects that many existing treatments display. We have a number of other promising candidates in the pipeline and we’re looking forward to seeing these progress into development in the near future.”

See the article in full at

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.